Endometrial Serous Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: END085 MIFTS: 47	Endometrial Serous Adenocarcinoma Categories: Cancer diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Endometrial Serous Adenocarcinoma

MalaCards integrated aliases for Endometrial Serous Adenocarcinoma:

Name: Endometrial Serous Adenocarcinoma ¹¹ ⁵ ¹⁴ ¹⁶ ⁷¹ ³³

Uterine Serous Carcinoma ¹¹ ⁷⁵

Uterine Corpus Serous Adenocarcinoma ¹¹

Uterine Papillary Serous Carcinoma ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of female genital organs

Malignant neoplasms of corpus uteri

Endometrial serous adenocarcinoma

External Ids:

Disease Ontology ¹¹ DOID:5750

NCIt ⁴⁹ C27838

EFO ¹⁶ EFO_1000238

ICD11 ³³ 225222541

UMLS ⁷¹ C0854924 C1336921

Sources

Summaries for Endometrial Serous Adenocarcinoma

Disease Ontology: ¹¹ A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia.

MalaCards based summary: Endometrial Serous Adenocarcinoma, also known as uterine serous carcinoma, is related to papillary serous adenocarcinoma and apocrine adenocarcinoma. An important gene associated with Endometrial Serous Adenocarcinoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are Disease and PIP3 activates AKT signaling. The drugs Lenograstim and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include uterus, lymph node and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased cell death in HCT116 cells

Wikipedia: ⁷⁵ Uterine serous carcinoma is a malignant form of serous tumor that originates in the uterus. It is an... more...

Sources

Related Diseases for Endometrial Serous Adenocarcinoma

Diseases related to Endometrial Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 291)

#	Related Disease	Score	Top Affiliating Genes
1	papillary serous adenocarcinoma	31.7	WT1 TP53 ERBB2 BRCA1
2	apocrine adenocarcinoma	30.5	TP53 PIK3CA ERBB2
3	ovarian serous carcinoma	30.5	WT1 TP53 MIR10B BRCA1
4	endometrial hyperplasia	30.3	TP53 PTEN ARID1A
5	papillary adenocarcinoma	30.3	TP53 MIR10B ERBB2 BRCA1
6	cervix carcinoma	30.2	TP53 PTEN PIK3CA MIR34C MIR139 ERBB2
7	endometrial adenocarcinoma	30.1	TP53 PTEN POLE MIR34C
8	gastrointestinal stromal tumor	30.0	TP53 PTEN PIK3CA ERBB2
9	wilms tumor 1	30.0	WT1 TP53 PTEN ERBB2 BRCA1
10	cervical squamous cell carcinoma	29.9	TP53 PTEN PIK3CA FBXW7 ARID1A
11	high grade glioma	29.9	TP53 PTEN PIK3CA MIR10B ATM
12	peripheral nervous system disease	29.9	TP53 PTEN MIR34B ERBB2 BRCA1 ATM
13	inherited cancer-predisposing syndrome	29.8	TP53 PTEN POLE BRCA1 ATM
14	bap1 tumor predisposition syndrome	29.8	TP53 PTEN POLE BRCA1 ATM
15	adenocarcinoma	29.8	TP53 PTEN PIK3CA ERBB2 CCNE1 ATM
16	carcinosarcoma	29.7	WT1 TP53 PTEN PPP2R1A PIK3CA FBXW7
17	hereditary breast ovarian cancer syndrome	29.7	TP53 PTEN POLE PIK3CA ERBB2 BRCA1
18	fanconi anemia, complementation group a	29.7	TP53 PTEN BRCA1 ATM ARID1A
19	ovary adenocarcinoma	29.6	WT1 TP53 PTEN PIK3CA ERBB2 BRCA1
20	mismatch repair cancer syndrome	29.4	TP53 PTEN POLE PIK3CA BRCA1 ATM
21	ovarian cancer	29.3	WT1 TP53 PTEN PPP2R1A PIK3CA MIR34C
22	endometrioid ovary carcinoma	29.3	WT1 TP53 PTEN PPP2R1A POLE PIK3CA
23	mixed cell type cancer	29.3	WT1 TP53 PTEN PPP2R1A POLE PIK3CA
24	endometrial cancer	29.1	WT1 TP53 PTEN PIK3CA FBXW7 ERBB2
25	uterine carcinosarcoma	29.1	TP53 PTEN PPP2R1A POLE PIK3CA FBXW7
26	lynch syndrome	29.1	TP53 PTEN PPP2R1A POLE PIK3CA MIR139
27	serous cystadenocarcinoma	28.6	WT1 TP53 PTEN PPP2R1A POLE PIK3CA
28	breast cancer	28.0	WT1 TP53 PTEN PPP2R1A POLE PIK3CA
29	epithelial-myoepithelial carcinoma	10.5
30	uterine anomalies	10.5
31	papillary carcinoma	10.4
32	maxillary sinus adenocarcinoma	10.3	TP53 ATM
33	apocrine adenosis of breast	10.3	TP53 ERBB2
34	esophagus small cell carcinoma	10.3	PIK3CA ERBB2
35	high-grade astrocytoma	10.3	TP53 PTEN
36	esophagus verrucous carcinoma	10.3	TP53 PIK3CA
37	parotid gland cancer	10.3	TP53 ERBB2
38	gestational ovarian choriocarcinoma	10.3	TP53 ERBB2
39	breast metaplastic carcinoma	10.3	TP53 ERBB2
40	basaloid lung carcinoma	10.3	TP53 BRCA1
41	comedo carcinoma	10.3	TP53 ERBB2
42	adrenocortical carcinoma, hereditary	10.3
43	primary agammaglobulinemia	10.3
44	pleomorphic adenoma carcinoma	10.3	TP53 ERBB2
45	familial ovarian cancer	10.3	TP53 POLE ATM
46	clear cell adenofibroma	10.3	PIK3CA ARID1A
47	penile benign neoplasm	10.3	TP53 PIK3CA
48	factor vii deficiency	10.2
49	neutropenia	10.2
50	ovarian epithelial cancer	10.2

Graphical network of the top 20 diseases related to Endometrial Serous Adenocarcinoma:

Sources

Symptoms & Phenotypes for Endometrial Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 29)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-1	9.91	POLE
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-123	9.91	POLE
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-137	9.91	BRCA1
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-139	9.91	BRCA1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	9.91	PTEN
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	9.91	PTEN
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	9.91	ERBB2
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	9.91	ARID1A BRCA1 ERBB2 POLE PTEN
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-176	9.91	ARID1A
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-186	9.91	ARID1A
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	9.91	ARID1A
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	9.91	POLE
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-204	9.91	BRCA1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-207	9.91	ERBB2 POLE
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-211	9.91	BRCA1
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.91	ARID1A
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	9.91	PTEN
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	9.91	ERBB2 POLE
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	9.91	PTEN
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.91	ARID1A
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.91	ERBB2
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.91	ERBB2 POLE PTEN
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-66	9.91	PTEN
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	9.91	ARID1A
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.91	ERBB2 POLE
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	9.91	ERBB2 POLE PTEN
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	9.91	POLE
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-93	9.91	PTEN
29	Increased cell death in HCT116 cells	GR00103-A-0	9.26	CHD4 FBXW7 PIK3CA PPP2R1A

MGI Mouse Phenotypes related to Endometrial Serous Adenocarcinoma:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.32	ARID1A ATM BRCA1 CCNE1 ERBB2 FBXW7
2	endocrine/exocrine gland	MP:0005379	10.2	ARID1A ATM BRCA1 CCNE1 CHD4 ERBB2
3	normal	MP:0002873	10.19	ARID1A BRCA1 CCNE1 ERBB2 FBXW7 MIR499A
4	embryo	MP:0005380	10.17	ARID1A ATM BRCA1 CCNE1 CHD4 ERBB2
5	cellular	MP:0005384	10.15	ARID1A ATM BRCA1 CCNE1 CHD4 ERBB2
6	muscle	MP:0005369	10.08	ARID1A BRCA1 ERBB2 MIR499A PIK3CA PTEN
7	cardiovascular system	MP:0005385	10.06	ARID1A ATM BRCA1 CCNE1 CHD4 ERBB2
8	immune system	MP:0005387	10.03	ARID1A ATM BRCA1 CCNE1 CHD4 FBXW7
9	digestive/alimentary	MP:0005381	10.01	BRCA1 CCNE1 ERBB2 FBXW7 MIR139 PIK3CA
10	reproductive system	MP:0005389	9.85	ARID1A ATM BRCA1 CCNE1 ERBB2 FBXW7
11	mortality/aging	MP:0010768	9.83	ARID1A ATM BRCA1 CCNE1 CHD4 ERBB2
12	integument	MP:0010771	9.28	ATM BRCA1 CCNE1 ERBB2 FBXW7 PIK3CA

Sources

Drugs & Therapeutics for Endometrial Serous Adenocarcinoma

Drugs for Endometrial Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Everolimus

Approved

Phase 2, Phase 3

159351-69-6

70789204 6442177

Letrozole

Approved, Investigational

Phase 2, Phase 3

112809-51-5

3902

Trastuzumab

Approved, Investigational

Phase 2, Phase 3

180288-69-1

Pertuzumab

Approved

Phase 2, Phase 3

380610-27-5

Carboplatin

Approved

Phase 2, Phase 3

41575-94-4

10339178 38904

Metformin

Approved

Phase 2, Phase 3

1115-70-4, 657-24-9

4091

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Estrogens

Phase 2, Phase 3

Estrogen Receptor Antagonists

Phase 2, Phase 3

Estrogen Antagonists

Phase 2, Phase 3

Hormones

Phase 2, Phase 3

Hormone Antagonists

Phase 2, Phase 3

Aromatase Inhibitors

Phase 2, Phase 3

Immunologic Factors

Phase 2, Phase 3

Liposomal doxorubicin

Phase 3

Adjuvants, Immunologic

Phase 3

Immunosuppressive Agents

Phase 2, Phase 3

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Hypoglycemic Agents

Phase 2, Phase 3

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Nintedanib

Approved

Phase 2

656247-17-5

135423438 9809715

Anastrozole

Approved, Investigational

Phase 2

120511-73-1

2187

Olaparib

Approved

Phase 2

763113-22-0

23725625

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Niraparib

Approved, Investigational

Phase 2

1038915-60-4

24958200

Afatinib

Approved

Phase 2

439081-18-2, 850140-72-6

53445376 10184653

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Doxycycline

Approved, Investigational, Vet_approved

Phase 2

564-25-0

54671203

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Paclitaxel

Approved, Vet_approved

Phase 1, Phase 2

33069-62-4

36314

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Trebananib

Investigational

Phase 2

894356-79-7

Onapristone

Investigational

Phase 2

96346-61-1

5311505

Cediranib

Investigational

Phase 2

288383-20-0

9933475

Maleic acid

Experimental, Investigational

Phase 2

110-16-7, 110-17-8

444266 444972

MK-1775

Investigational

Phase 2

955365-80-7

24856436

Liver Extracts

Phase 2

Immunoglobulin Fc Fragments

Phase 2

Antineoplastic Agents, Hormonal

Phase 2

Anti-Bacterial Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Anti-Infective Agents

Phase 2

Epothilones

Phase 2

Epothilone B

Phase 2

4456137

Antifungal Agents

Phase 2

Antiprotozoal Agents

Phase 2

Interventional clinical trials:

(show top 50) (show all 54)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma	Unknown status	NCT00807768	Phase 3	Carboplatin;Paclitaxel
2	A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
3	CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation	Completed	NCT03285802	Phase 2, Phase 3	Letrozole;Everolimus
4	A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma	Recruiting	NCT05256225	Phase 2, Phase 3	Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
5	A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer	Active, not recruiting	NCT03914612	Phase 3	Carboplatin;Paclitaxel
6	A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Active, not recruiting	NCT02065687	Phase 2, Phase 3	Carboplatin;Metformin Hydrochloride;Paclitaxel
7	A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma	Active, not recruiting	NCT00942357	Phase 3	Carboplatin;Cisplatin;Paclitaxel
8	Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)	Active, not recruiting	NCT03422198	Phase 3
9	Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel	Active, not recruiting	NCT02501954	Phase 3	Cisplatin;Carboplatin;Paclitaxel
10	A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma	Completed	NCT00478426	Phase 2	Sunitinib Malate
11	A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations	Completed	NCT02728258	Phase 2	Copanlisib
12	A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
13	A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00888173	Phase 2	Brivanib Alaninate
14	A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01132820	Phase 2	Cediranib Maleate
15	A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
16	A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01642082	Phase 2
17	A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01225887	Phase 2	Nintedanib
18	A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium	Completed	NCT01210222	Phase 2
19	A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
20	Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC)	Completed	NCT00022620	Phase 2	paclitaxel
21	A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma	Completed	NCT00231868	Phase 2	Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
22	A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer	Recruiting	NCT04719273	Phase 2	Extended-release Onapristone;Anastrozole
23	A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer	Recruiting	NCT03660826	Phase 2	Capivasertib;Cediranib;Cediranib Maleate;Olaparib
24	Trial of Maintenance With Niraparib in Patients With Stage III, Stage IV or Platinum-sensitive Recurrent Uterine Serous Carcinoma	Recruiting	NCT04080284	Phase 2	Niraparib
25	A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Recruiting	NCT03668340	Phase 2	AZD1775
26	A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin/Taxol Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma	Recruiting	NCT04030000	Phase 1, Phase 2	Paclitaxel/Carboplatin
27	A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma	Recruiting	NCT04814108	Phase 2	ZN-c3
28	A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma	Recruiting	NCT02491099	Phase 2	Afatinib
29	A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer	Active, not recruiting	NCT01935934	Phase 2	Cabozantinib S-malate
30	A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	Active, not recruiting	NCT00492778	Phase 2	Cisplatin
31	A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Active, not recruiting	NCT00977574	Phase 2	Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
32	A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer	Active, not recruiting	NCT02874430	Phase 2	Metformin Hydrochloride;Doxycycline
33	A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma	Active, not recruiting	NCT04590248	Phase 2	Adavosertib
34	Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer	Not yet recruiting	NCT05231122	Phase 2
35	A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma	Terminated	NCT02112552	Phase 2	Paclitaxel;Carboplatin
36	A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC)	Terminated	NCT00506779	Phase 1, Phase 2	Imatinib Mesylate;Paclitaxel
37	Phase II Trial of Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer	Withdrawn	NCT03836157	Phase 2	Mirvetuximab Soravtansine;Bevacizumab
38	A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973	Completed	NCT01935973	Phase 1	Trametinib;Uprosertib
39	Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy	Completed	NCT00005840	Phase 1	Paclitaxel;Cisplatin
40	A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure	Completed	NCT00575952	Phase 1	Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
41	Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma	Completed	NCT00005830	Phase 1	Doxorubicin Hydrochloride;Cisplatin
42	Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer	Completed	NCT01440998	Phase 1	Carboplatin;Dasatinib;Paclitaxel
43	A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies	Recruiting	NCT04585958	Phase 1	Olaparib
44	Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)	Recruiting	NCT02020707	Phase 1	Nab-paclitaxel
45	Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer	Recruiting	NCT03120624	Phase 1	Ruxolitinib;Ruxolitinib Phosphate;Technetium Tc-99m Sodium Pertechnetate
46	A Phase I Study of Stereotactic Body Radiation Therapy for Patients With Limited Locoregional Recurrences of Ovarian and Uterine Serous Carcinoma	Active, not recruiting	NCT03325634	Phase 1
47	A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors	Active, not recruiting	NCT02142803	Phase 1	Sapanisertib
48	Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Active, not recruiting	NCT03552471	Phase 1	Rucaparib Camsylate
49	First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours	Not yet recruiting	NCT05498597	Phase 1	AMT-151
50	Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers	Completed	NCT02315469

Search NIH Clinical Center for Endometrial Serous Adenocarcinoma

Sources

Genetic Tests for Endometrial Serous Adenocarcinoma

Sources

Anatomical Context for Endometrial Serous Adenocarcinoma

Organs/tissues related to Endometrial Serous Adenocarcinoma:

MalaCards : Uterus, Lymph Node, Breast, Endothelial, Liver, Cervix, Myeloid

Sources

Publications for Endometrial Serous Adenocarcinoma

Articles related to Endometrial Serous Adenocarcinoma:

(show top 50) (show all 562)

#	Title	Authors	PMID	Year
1	Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma. ⁶²	Dong L...Yuan G	36428992	2022
2	Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness. ⁶²	Lopez-Mejia IC...Yeramian A	36409196	2022
3	Targeted Therapies in the Treatment of Uterine Serous Carcinoma. ⁶²	Tymon-Rosario JR...Santin AD	36447064	2022
4	Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. ⁶²	Kurnit KC...Soliman PT	36243601	2022
5	Optimal cytoreduction followed by chemoradiation in stage IVB uterine serous carcinoma. ⁶²	McEachron J...Lee YC	36096033	2022
6	HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy. ⁶²	Klc TR...Erickson BK	36114027	2022
7	Endoscopic Surgery Using Ultrasonic Energy Device for Tracheal Metastatic Tumor. ⁶²	Iwasaki M...Inoue M	34973186	2022
8	PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer. ⁶²	Jones W...Ganapathi R	36177381	2022
9	Immunosuppressive tumor microenvironment in uterine serous carcinoma via CCL7 signal with myeloid-derived suppressor cells. ⁶²	Mise Y...Baba T	35353883	2022
10	Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. ⁶²	Yadav G...Santin AD	35641325	2022
11	GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. ⁶²	Bruce SF...Fuh KC	35588308	2022
12	Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors. ⁶²	Prieto-Potin I...Rojo F	36010253	2022
13	[TXNDC17 protein overexpression in uterine papillary serous carcinoma is associated with clinicopathological characteristics and prognosis]. ⁶²	Peng QH...Zhang SF	36008321	2022
14	HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas. ⁶²	Ersoy E...Otis CN	34320531	2022
15	Oncologic safety of laparoscopic surgery for women with apparent early-stage uterine serous carcinoma: A multi-institutional retrospective cohort study. ⁶²	Xu Y...Tian Y	34561857	2022
16	Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning. ⁶²	Nolin AC...Darcy KM	35624045	2022
17	Evaluation of a Patient With Non-Myoinvasive Uterine Serous Carcinoma Confined to a Polyp and Positive Peritoneal Washings With Somatic ARHGAP35 and KRAS Mutations. ⁶²	Silverwood SM...Gressel G	35949786	2022
18	Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer. ⁶²	Gatius S...Eritja N	35740505	2022
19	Incidence of omental metastasis in uterine serous carcinoma: a systematic review and meta-analysis. ⁶²	Xu H...Tian Y	35489712	2022
20	Endometrial Polyp in Postmenopausal Women. ⁶²	Hui P	35512230	2022
21	Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer. ⁶²	Anderson EM...Kamrava M	35216809	2022
22	Synchronous uterine serous carcinoma and ovarian sex cord stromal tumor (thecoma)-A rare first case report. ⁶²	Sethi N...Yadav ML	35435389	2022
23	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. ⁶²	Stover EH...Konstantinopoulos PA	35434236	2022
24	Evaluation of Saccharomyces cerevisiae-like 1 (SEC14L1) in Gynecologic Malignancies Shows Overexpression in Endometrial Serous Carcinoma. ⁶²	Banet N...Quddus MR	35283446	2022
25	Evaluation of the incidence and clinical significance of WT-1 expression in uterine serous carcinoma. ⁶²	McEachron J...Lee YC	35024404	2022
26	Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records. ⁶²	Monk BJ...Banerjee S	34952707	2022
27	Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. ⁶²	O'Connor CM...Narla G	34921012	2022
28	ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma. ⁶²	Liu J...Oaknin A	34716177	2022
29	The top 100 most cited papers on endometrial carcinoma: A bibliometric analysis. ⁶²	Xiao P...Wang G	36059668	2022
30	Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer. ⁶²	Sendo K...Nagase S	35106124	2022
31	Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancer. ⁶²	Buckingham L...Bae-Jump V	35812065	2022
32	Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies in uterine papillary serous carcinoma. ⁶²	Deleuze A...Le Du F	34980663	2022
33	Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center. ⁶²	Ditto A...Raspagliesi F	34753617	2022
34	Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. ⁶²	Assem H...Hui P	34508766	2021
35	Linking altered microRNA expression to racial disparities in uterine serous carcinoma. ⁶²	Wei JJ	34836615	2021
36	Inspection for micrometastasis is essential for predicting the prognosis of serous endometrial intraepithelial carcinoma: Case report and literature review. ⁶²	Yoshioka T...Miyagi E	34494349	2021
37	MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma. ⁶²	Lee L...Konstantinopoulos PA	34607711	2021
38	Concomitant diagnosis of endometrial and breast cancer - does the sequence matters? ⁶²	Stern T...Safra T	34621946	2021
39	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. ⁶²	Tymon-Rosario J...Santin AD	34452746	2021
40	Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma. ⁶²	Chambers LM...Vargas R	34761096	2021
41	Correction: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel. ⁶²	Seino M...Nagase S	34786186	2021
42	What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience. ⁶²	Liontos M...Zagouri F	34898589	2021
43	Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. ⁶²	Tymon-Rosario J...Santin AD	34372971	2021
44	A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation. ⁶²	T Danley K...Usha L	34018286	2021
45	Matched-pair Analysis for Survival Endpoints Between Women With Early-stage Uterine Carcinosarcoma and Uterine Serous Carcinoma. ⁶²	Yahya JB...Elshaikh MA	34265785	2021
46	Uterine serous carcinoma: key advances and novel treatment approaches. ⁶²	Ferriss JS...Fader AN	34210768	2021
47	Impact of positive cytology in uterine serous carcinoma: A reassessment. ⁶²	Corey L...Bandyopadhyay S	34345643	2021
48	Uterine serous carcinoma. ⁶²	Bogani G...Monk BJ	33934848	2021
49	Clinicopathological characteristics and prognosis of uterine serous carcinoma: A SEER program analysis of 1016 cases. ⁶²	Han Y...Liu C	33870589	2021
50	Rare brain metastasis with unusual characteristics in a late recurrence of stage IIIA uterine papillary serous carcinoma. ⁶²	Crain CN...Punch G	35047191	2021

Sources

Genes for Endometrial Serous Adenocarcinoma

Genes related to Endometrial Serous Adenocarcinoma (1 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ATM	ATM Serine/Threonine Kinase	Protein Coding	404.41	Pathogenic ⁵ DISEASES inferred ¹⁴
2	MIR139	MicroRNA 139	RNA Gene	7.83	DISEASES inferred ¹⁴ ¹⁴
3	MIR449B	MicroRNA 449b	RNA Gene	7.39	DISEASES inferred ¹⁴ ¹⁴
4	MIR34B	MicroRNA 34b	RNA Gene	7.2	DISEASES inferred ¹⁴ ¹⁴
5	PPP2R1A	Protein Phosphatase 2 Scaffold Subunit Aalpha	Protein Coding	6.92	DISEASES inferred ¹⁴
6	MIR135A1	MicroRNA 135a-1	RNA Gene	6.87	DISEASES inferred ¹⁴ ¹⁴
7	TP53	Tumor Protein P53	Protein Coding	6.81	DISEASES inferred ¹⁴
8	MIR34C	MicroRNA 34c	RNA Gene	6.81	DISEASES inferred ¹⁴ ¹⁴
9	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.7	DISEASES inferred ¹⁴
10	MIR10B	MicroRNA 10b	RNA Gene	6.63	DISEASES inferred ¹⁴ ¹⁴
11	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.51	DISEASES inferred ¹⁴
12	MIR499A	MicroRNA 499a	RNA Gene	6.37	DISEASES inferred ¹⁴ ¹⁴
13	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.21	DISEASES inferred ¹⁴
14	POLE	DNA Polymerase Epsilon, Catalytic Subunit	Protein Coding	6.19	DISEASES inferred ¹⁴
15	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	6.11	DISEASES inferred ¹⁴
16	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	5.9	DISEASES inferred ¹⁴
17	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	5.84	DISEASES inferred ¹⁴
18	CCNE1	Cyclin E1	Protein Coding	5.76	DISEASES inferred ¹⁴
19	CHD4	Chromodomain Helicase DNA Binding Protein 4	Protein Coding	5.73	DISEASES inferred ¹⁴
20	WT1	WT1 Transcription Factor	Protein Coding	5.72	DISEASES inferred ¹⁴
21	AURKB	Aurora Kinase B	Protein Coding	5.7	DISEASES inferred ¹⁴
22	CDC42SE2	CDC42 Small Effector 2	Protein Coding	5.69	DISEASES inferred ¹⁴
23	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	5.64	DISEASES inferred ¹⁴

Sources

Variations for Endometrial Serous Adenocarcinoma

ClinVar genetic disease variations for Endometrial Serous Adenocarcinoma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	ATM		DEL	Pathogenic	1174013		GRCh37: 11:108098332-108236255 GRCh38:

Copy number variations for Endometrial Serous Adenocarcinoma from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	52344	11	16200000	21700000	Copy number	SAA1	Uterine serous papillary cancer

Sources

Expression for Endometrial Serous Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Serous Adenocarcinoma.

Sources

Pathways for Endometrial Serous Adenocarcinoma

Pathways related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 41)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.75	TP53 PTEN PPP2R1A PIK3CA FBXW7 ERBB2
2	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.01	CHD4 ERBB2 PIK3CA PPP2R1A PTEN TP53
3	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.9	BRCA1 CCNE1 PIK3CA PPP2R1A PTEN TP53
4	Regulation of TP53 Activity ⁶⁶ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁶ Regulation of TP53 Activity through Methylation ⁶⁶ Regulation of TP53 Activity through Phosphorylation ⁶⁶ Transcriptional Regulation by TP53 ⁶⁶	12.87	TP53 PTEN PPP2R1A CHD4 CCNE1 BRCA1
5	Cell Cycle Checkpoints ⁶⁶ Show member pathways G2/M Checkpoints ⁶⁶	12.7	TP53 PPP2R1A CCNE1 BRCA1 ATM
6	Malignant pleural mesothelioma ⁷⁴	12.64	TP53 PTEN PIK3CA CCNE1 BRCA1 ATM
7	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.53	TP53 POLE FBXW7 CCNE1 BRCA1 ATM
8	DNA Damage ³	12.45	ATM BRCA1 CCNE1 PPP2R1A TP53
9	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.41	TP53 PTEN PIK3CA ERBB2
10	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.38	TP53 PIK3CA ERBB2 ATM
11	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.37	TP53 PTEN PIK3CA ERBB2 BRCA1 ATM
12	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.31	PPP2R1A FBXW7 CCNE1 BRCA1
13	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.19	TP53 POLE CCNE1 ATM
14	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.17	TP53 PTEN PIK3CA ERBB2
15	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.12	TP53 PTEN CCNE1 BRCA1 ATM
16	Integrated breast cancer pathway ⁷⁴	12.09	TP53 PTEN BRCA1 ATM
17	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.06	TP53 CCNE1 BRCA1 ATM
18	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ G1-S Phase Transition ⁶⁴	12.05	TP53 PPP2R1A CCNE1 ATM
19	Small cell lung cancer ⁷⁴	11.86	TP53 PTEN PIK3CA CCNE1
20	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.85	TP53 BRCA1 ATM
21	p53 transcriptional gene network ⁷⁴	11.84	PTEN MIR34C MIR34B CCNE1
22	Retinoblastoma gene in cancer ⁷⁴	11.79	TP53 POLE CCNE1
23	ATM Pathway ⁶⁴ Show member pathways ATM signaling pathway ⁷⁴	11.78	TP53 CCNE1 BRCA1 ATM
24	DNA damage response (only ATM dependent) ⁷⁴	11.77	TP53 PTEN PIK3CA ERBB2 ATM
25	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.76	TP53 BRCA1 ATM
26	DNA IR-damage and cellular response via ATR ⁷⁴	11.75	ATM BRCA1 TP53
27	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.71	TP53 PPP2R1A ATM
28	16p11.2 proximal deletion syndrome ⁷⁴	11.7	TP53 PTEN PPP2R1A
29	Head and neck squamous cell carcinoma ⁷⁴	11.7	ERBB2 PIK3CA PTEN TP53
30	E2F transcription factor network ⁶¹	11.64	CCNE1 BRCA1 ATM
31	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.57	TP53 PTEN PIK3CA
32	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.42	ATM BRCA1 CCNE1 TP53
33	Integrated cancer pathway ⁷⁴	11.31	TP53 PTEN BRCA1 ATM
34	miRNA regulation of p53 pathway in prostate cancer ⁷⁴	11.27	TP53 PTEN ATM
35	miRNAs involved in DNA damage response ⁷⁴	11.26	TP53 MIR449B MIR34C MIR34B CCNE1 ATM
36	GADD45 Pathway ⁶⁴	11.13	ATM BRCA1 CCNE1 TP53
37	BARD1 signaling events ⁶¹	11.02	TP53 CCNE1 BRCA1 ATM
38	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.02	TP53 PTEN PIK3CA FBXW7 ERBB2 BRCA1
39	DNA Damage Induced 14-3-3Sigma Signaling ⁶⁴	10.74	TP53 CCNE1 BRCA1 ATM
40	SMC1/SMC3 role in DNA damage - Cornelia de Lange Syndrome ⁷⁴	10.71	BRCA1 ATM
41	PLK3 signaling events ⁶¹	10.36	TP53 CCNE1 ATM

Sources

GO Terms for Endometrial Serous Adenocarcinoma

Biological processes related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of cell cycle	GO:0051726	9.86	TP53 PTEN CCNE1 BRCA1 ATM
2	phosphatidylinositol 3-kinase signaling	GO:0014065	9.85	PTEN PIK3CA ERBB2
3	female meiotic nuclear division	GO:0007143	9.78	PPP2R1A ATM
4	negative regulation of protein kinase B signaling	GO:0051898	9.76	PTEN MIR34C MIR34B
5	negative regulation of cell growth	GO:0030308	9.76	BRCA1 PPP2R1A TP53 WT1
6	heart development	GO:0007507	9.61	WT1 TP53 PTEN ERBB2 ATM
7	positive regulation of connective tissue replacement	GO:1905205	9.43	MIR34C MIR34B
8	chromosome organization involved in meiotic cell cycle	GO:0070192	9.4	CCNE1 ATM
9	miRNA-mediated gene silencing	GO:0035195	9.4	MIR499A MIR449B MIR34C MIR34B MIR139 MIR135A1
10	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.32	MIR34C MIR34B

Molecular functions related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.5	TP53 MIR499A MIR34C MIR34B MIR139 MIR10B
2	mRNA base-pairing translational repressor activity	GO:1903231	9.1	MIR499A MIR34C MIR34B MIR139 MIR135A1 MIR10B